BiondVax universal flu vaccine improves immune response against H3N2
The results are from the BVX-005 phase II trial from 2012. At that time, the H3N2 influenza strain did not exist. In 2015, there was an H3N2 epidemic within the U.S.
"We are happy that the participants which received our vaccine in the trial three years ago present a higher immunogenicity, even to actual flu strains in circulation now,” BiondVax President and CEO Ron Babecoff said. “The independently provided statistical analysis we reported today is very important as it demonstrates that M-001 provides a safety net by broadening the immunogenicity to existing and future flu strains -- in this case, against a specific flu strain that back when the trial was conducted, did not yet exist. If our vaccine was approved by the necessary regulatory bodies and available in the market during the last winter, we believe that the recent epidemic could have been prevented. These results are another important data point showing the importance of our work for global public health and in particular for the elderly which are most vulnerable to this dangerous virus."